InsidersTradesSigma
Follow the 리가켐바이오 share price and the full insider trade history of the company, a publicly traded company based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 리가켐바이오 has recorded 9 public disclosures. Market capitalisation: €3,469bn. The latest transaction was reported on 24 July 2026 (Purchase). Among the most active insiders: PANORIONCORP.LIMITED. All data is openly available.
Analysts rate 리가켐바이오 Buy (bullish), based on 6 analysts. Average price target: ₩211,667.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
LigaChemBio 是一家专注于医疗保健和制药领域的公司，在 XKRX 市场上市。它致力于开发创新的疾病治疗解决方案。